Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
- PMID: 29071761
- DOI: 10.1111/joim.12708
Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy
Abstract
Programmed death 1 (PD-1) is an immune checkpoint molecule that negatively regulates T-cell immune function through the interaction with its ligand PD-L1. Blockage of this interaction unleashes the immune system to fight cancer. Immunotherapy using PD-1 blockade has led to a paradigm shift in the field of cancer drug discovery, owing to its durable effect against a wide variety of cancers with limited adverse effects. A brief history and development of PD-1 blockade, from the initial discovery of PD-1 to the recent clinical output of this therapy, have been summarized here. Despite its tremendous clinical success rate over other cancer treatments, PD-1 blockade has its own pitfall; a significant fraction of patients remains unresponsive to this therapy. The key to improve the PD-1 blockade therapy is the development of combination therapies. As this approach has garnered worldwide interest, here, we have summarized the recent trends in the development of PD-1 blockade-based combination therapies and the ongoing clinical trials. These include combinations with checkpoint inhibitors, radiation therapy, chemotherapy and several other existing cancer treatments. Importantly, FDA has approved PD-1 blockade agent to be used in combination with either CTLA-4 blockade or chemotherapy. Responsiveness to the PD-1 blockade therapy is affected by tumour and immune system-related factors. The role of the immune system, especially T cells, in determining the responsiveness has been poorly studied compared with those factors related to the tumour side. Energy metabolism has emerged as one of the important regulatory mechanisms for the function and differentiation of T cells. We have documented here the recent results regarding the augmentation of PD-1 blockade efficacy by augmenting mitochondrial energy metabolism of T cell.
Keywords: PD-1 blockade; T cell; cancer immunotherapy; combination therapies; mitochondrial energy metabolism.
© 2017 The Association for the Publication of the Journal of Internal Medicine.
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2. Int Immunopharmacol. 2018. PMID: 29990692 Review.
-
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.J Oncol Pharm Pract. 2015 Dec;21(6):451-67. doi: 10.1177/1078155214538087. Epub 2014 Jun 9. J Oncol Pharm Pract. 2015. PMID: 24917416 Review.
-
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.Elife. 2020 Mar 3;9:e52330. doi: 10.7554/eLife.52330. Elife. 2020. PMID: 32122466 Free PMC article.
-
Current issues and perspectives in PD-1 blockade cancer immunotherapy.Int J Clin Oncol. 2020 May;25(5):790-800. doi: 10.1007/s10147-019-01588-7. Epub 2020 Jan 3. Int J Clin Oncol. 2020. PMID: 31900651 Free PMC article. Review.
Cited by
-
Design, Synthesis, and Study of a Novel RXPA380-Proline Hybrid (RXPA380-P) as an Antihypertensive Agent.ACS Omega. 2022 Sep 23;7(39):35035-35043. doi: 10.1021/acsomega.2c03813. eCollection 2022 Oct 4. ACS Omega. 2022. PMID: 36211060 Free PMC article.
-
Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.Expert Rev Clin Pharmacol. 2020 Oct;13(10):1147-1158. doi: 10.1080/17512433.2020.1817737. Epub 2020 Sep 11. Expert Rev Clin Pharmacol. 2020. PMID: 32862726 Free PMC article.
-
p53 mutation and deletion contribute to tumor immune evasion.Front Genet. 2023 Feb 20;14:1088455. doi: 10.3389/fgene.2023.1088455. eCollection 2023. Front Genet. 2023. PMID: 36891151 Free PMC article. Review.
-
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches.Front Immunol. 2020 May 12;11:849. doi: 10.3389/fimmu.2020.00849. eCollection 2020. Front Immunol. 2020. PMID: 32477347 Free PMC article. Review.
-
Mechanisms of esophageal cancer metastasis and treatment progress.Front Immunol. 2023 Jun 8;14:1206504. doi: 10.3389/fimmu.2023.1206504. eCollection 2023. Front Immunol. 2023. PMID: 37359527 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials